## UK Approves First Oral Version of Wegovy Weight-Loss Drug

British regulators have given the green light to a pill-based version of the widely used weight-loss medication Wegovy, marking a significant milestone in obesity treatment. The approval means patients across the UK will soon be able to obtain the tablet form through a prescription, offering an alternative to the injectable version that many have come to rely on.

### A More Convenient Option for Patients

Danish pharmaceutical giant Novo Nordisk, which manufactures the drug, says the once-daily tablet could prove far more practical for many users compared to administering a weekly injection. One notable advantage is that the tablets do not require refrigeration, unlike the injectable version — making storage and travel considerably more straightforward for patients.

The Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed its approval, making this the first tablet of its kind to receive clearance from the regulatory body. According to the MHRA, patients should begin on a starting dose of 1.5mg once daily, gradually increasing through 4mg and 9mg to a maximum of 25mg, with at least one month spent at each dosage level. The tablet must be taken on an empty stomach for optimal effectiveness.

Those already receiving private treatment via the 2.4mg semaglutide weekly injection can transition directly onto the 25mg daily tablet form.

### NHS Availability Still Pending

Despite regulatory approval, the pill will not be accessible through the NHS in the near term. The National Institute for Health and Care Excellence (NICE), the body responsible for recommending treatments for NHS use, has confirmed that Novo Nordisk has not yet formally submitted an application for consideration. However, NICE noted it is currently engaged in active discussions with the company.

In the meantime, a number of high street and online pharmacies are preparing to offer the tablet through private prescribing services within the coming weeks.

### How the Drug Works

Much like its injectable counterpart, the Wegovy pill contains semaglutide — an active compound that mimics the effects of a naturally occurring hormone known as GLP-1. This hormone works by suppressing appetite and slowing the digestive process, helping individuals feel fuller for longer and reducing overall food intake.

Clinical trials have demonstrated the tablets to be both safe and effective, though patients should expect it to take several months before experiencing the full benefits. As with the injection, there is also a risk of weight returning once the medication is discontinued.

### Cost and Wider Availability

The exact pricing of Wegovy tablets in the UK has yet to be confirmed. However, when the drug launched in the United States — where it is already on sale — the manufacturer listed the entry-level 1.5mg dose at approximately $149 (around £110) per month.

Olivier Picard, Chair of the National Pharmacy Association, described the approval as a meaningful development, highlighting that it could benefit patients who are unwilling or unable to use injectable treatments. He also suggested that the pill format could help reduce the overall cost of weight management treatment over time. Pharmacies are currently awaiting further official guidance on when the product will be made available to patients.

### Important Considerations for Users

Experts stress that GLP-1 medications are intended as a serious medical intervention for obesity — not a cosmetic or short-term solution. Health professionals strongly caution against misusing these drugs for superficial purposes such as achieving a "beach body."

As with any medication, side effects are possible. Commonly reported issues include nausea, vomiting, diarrhoea, and constipation. Patients are also advised to maintain a balanced diet and engage in regular physical activity alongside treatment.

With more than 16 million UK adults — roughly a third of the population — classified as obese, the arrival of an accessible oral treatment option represents a potentially important step forward in tackling one of the country's most pressing public health challenges. Several other pharmaceutical companies are also developing or have already launched competing products in this rapidly expanding market.

The UK's MHRA has approved an oral version of Wegovy for the first time. Find out how the daily pill works, its cost, and NHS availability.

Wegovy Weight-Loss Pill Approved for Use in the UK

a981e950-6592-11f1-be7e-9d9e15bac6ec.jpg

Wegovy Weight-Loss Drug Now Available in Pill Form Across the UK

## UK Launches Mass Meningitis B Vaccination Programme for Young Adults

Approximately one million young people across England, Wales, and Scotland are set to be offered a meningitis B vaccine as part of a significant one-off public health initiative. The programme has been triggered by the UK's largest and fastest-spreading outbreak of meningitis B on record, which emerged in Kent earlier this year, along with two additional concerning clusters identified in Weymouth, Dorset, and Reading, Berkshire.

## Who Is Eligible for the Vaccine?

The two-dose MenB vaccination programme is designed to reach those considered at the highest immediate risk. Eligibility broadly covers:

- **Year 13 pupils** in England and Wales, and **S6 students** in Scotland
- **Those aged 18 to 25** who are entering university or residential further education for the first time this autumn
- **International students** under the age of 25 beginning their first year are encouraged to receive their initial dose before arriving in the UK where possible

Health officials have highlighted that young people transitioning into university environments face elevated risk due to increased social mixing, communal living arrangements, and behaviours such as sharing drinks or vapes — all of which can facilitate the spread of meningococcal bacteria.

## A Devastating Loss That Underscores the Urgency

The human cost of meningitis B is painfully illustrated by the story of Aaron Mills, an 18-year-old from Kidderminster, Worcestershire, who passed away in January 2026. Aaron had recently begun studying at John Moores University in Liverpool and was home for the Christmas holidays when he developed what appeared to be mild flu-like symptoms.

On 30 December, he went to bed complaining of a headache. Just thirty minutes later, his family found him fitting and unresponsive. He died shortly after.

His father revealed that the family had assumed Aaron was protected, as he had previously received a meningitis vaccine. However, they later learned that different vaccines target different strains of the disease. The MenACWY vaccine, routinely offered to teenagers at age 14, covers separate strains and does not protect against meningitis B.

"The impact this has had on the family and friends is horrific. The pain is unbearable," his father said.

## How and When Can Young People Get Vaccinated?

### England

In England, the two doses will be available through community pharmacies during **July and August**. Importantly, recipients do not need to attend the same pharmacy for both injections. Year 13 students will be contacted directly via the NHS app, text message, email, or letter depending on their health records. Those aged 18 to 25 starting university for the first time can book appointments directly with participating pharmacies.

### Wales

The Welsh vaccination programme will run from **July through to December**. Young people aged 17 to 18 can expect a letter from their local health board from early July, while those aged 18 to 25 entering higher education will be able to contact their health board later that month.

### Scotland

Scotland's programme is also scheduled to begin in **July**, with further rollout details to follow.

### Northern Ireland

Authorities have confirmed that Northern Ireland will launch a similar programme in due course.

Two doses are required for maximum protection, with a minimum interval of 28 days between each injection.

## Government Response and Public Health Rationale

England's Secretary of State for Health and Social Care, James Murray, emphasised the seriousness of the current situation, stating that the Kent outbreak and subsequent clusters suggest a possible shift in how meningitis B is spreading through the population.

"While we assess the latest evidence, we are acting now to help protect young people at highest immediate risk as they enter university and residential colleges this autumn," Murray said. "By offering two doses of the jabs ahead of the academic year, we will help reduce the risk of serious illness and larger outbreaks of this horrendous disease."

Meningococcal disease can progress rapidly into life-threatening conditions, making early vaccination critical. Health officials are urging all eligible individuals to take up the offer as promptly as possible to ensure full protection before the autumn term begins.

The UK is offering meningitis B vaccines to one million young people ahead of autumn term following record outbreaks. Find out if you or your child is eligible.

MenB Vaccine Offered to One Million UK Young People

5227f710-6625-11f1-8e1d-bbbb1017d210.jpg

England, Wales and Scotland Launch MenB Vaccine Drive for One Million Young People

## Socioeconomic Conditions Are Physically Rewiring Children's Brains

A landmark study published in the journal *Science* has revealed that where a child grows up may matter far more to their brain development than previously understood. Analyzing data from over 2,300 children between the ages of 9 and 10, researchers discovered that socioeconomic factors — including household income, access to education, and neighborhood quality — are the dominant drivers of measurable differences in brain structure and function.

## What the Research Found

Using MRI scans drawn from the federally funded Adolescent Brain Cognitive Development (ABCD) Study, scientists identified clear structural and network-based differences in children's brains. When they ranked every possible contributing factor by influence, the results were striking: nearly every top-ranking variable was tied to socioeconomic opportunity.

Scott Marek, the study's lead author and an assistant professor of radiology at WashU School of Medicine, admitted the findings initially caught the team off guard. "The pattern that emerged was, at first, very confusing to us," he said. "We need to find out how socioeconomics is becoming biologically embedded."

Notably, these brain differences were concentrated in regions responsible for sensory processing and motor control — not higher cognitive areas like memory or attention.

## The Sleep, Stress, and Screen Time Connection

Researchers dug deeper to understand the mechanism behind these changes. Their investigation pointed to brain circuits that regulate wakefulness and alertness — circuits known to be disrupted by chronic stress, poor sleep, and excessive screen time.

Children raised in lower-income neighborhoods with limited social resources were found to experience all three of these stressors at significantly higher rates. The cumulative effect appears to leave a measurable biological imprint on developing brains.

"The data are screaming that we should be looking at sleep, stress, and screens if we want to get somewhere," Marek noted, while clarifying that the study establishes association rather than direct causation.

## Challenging Earlier Assumptions

The findings also call into question a body of prior research that examined brain development through the lens of IQ and mental health alone — without accounting for the overriding influence of socioeconomic environment.

Dr. Theodore D. Satterthwaite, an associate professor at the University of Pennsylvania Perelman School of Medicine and co-author of an accompanying perspective piece, suggested that some of those earlier studies "may require re-evaluation." By failing to control for socioeconomic variables, those studies may have drawn misleading conclusions about the relationship between cognitive performance and brain structure.

## A Growing Body of Evidence

Dr. Nico Dosenbach, a co-author of the new study and professor at WashU Medicine in St. Louis, emphasized just how dominant the socioeconomic variable proved to be. "Socioeconomics was, by a wide margin, absolutely the dominant variable," he said, noting that factors like IQ and mental health did show a modest influence — but nothing comparable.

Russell Poldrack, a psychology professor at Stanford University who was not involved in the research, described the study as a powerful reminder that "the environment in which we grow up and live has powerful impacts on our brain."

For researchers, policymakers, and parents alike, the message is increasingly difficult to ignore: childhood poverty and neighborhood disadvantage are not just social issues — they are neurological ones.

A new study of 2,300 children finds socioeconomic conditions like income and neighborhood quality are the top drivers of measurable brain differences.

How Socioeconomic Factors Shape Children's Brain Development

large_png

medium_png

small_png

thumbnail_png

How Your Zip Code Shapes Your Child's Brain Development

## A Remarkable Career Bridging Journalism and Public Health

Rachel Downey, a distinguished health and social affairs journalist who later became a leading communications strategist within the United Kingdom's health sector, has passed away at the age of 60 following renal failure. Her career spanned decades of meaningful work — from the newsrooms of London to the corridors of health policy — and left a lasting impression on everyone who worked alongside her.

Her husband, to whom she was married from 1999, remembered her as someone who possessed an exceptional ability to take complex, often sensitive health issues and translate them into clear, accessible communications for the general public. It was, he noted, demanding and vitally important work — and Rachel did it extraordinarily well.

## Final Role: Amplifying the Voices of Harmed Patients

In the final chapter of her professional life, Rachel served as Head of Public Relations at the Office of the Patient Safety Commissioner — a role that seemed, in many respects, perfectly suited to her talents and values. The Office exists to give a platform to patients who have suffered harm, to hold systems accountable, and to push for meaningful, systemic change.

During her time there, Rachel took the lead on communications for several landmark initiatives. Among the most significant was **Martha's Rule**, a groundbreaking policy granting patients and their families the legal right to request an urgent clinical review if they feel their condition is worsening and their concerns are going unheard.

She was also instrumental in raising public awareness around the **Hughes Report**, which examined financial redress for individuals harmed by the prescription drug sodium valproate and by pelvic mesh implants. More recently, she spearheaded communications for the **Safety Gap Report** — a commissioner-led investigation into disparities in patient safety outcomes across different demographic groups, and a call to bridge the gap between the care patients are promised and the care they actually receive.

## Roots in Dublin and a Passion for Journalism

Rachel was born in Dublin, the daughter of James Downey — a prominent political journalist who wrote for both the *Irish Times* and the *Irish Independent* — and his wife Moira, née Stevenson. Growing up in a household steeped in the written word, Rachel's own passion for journalism was ignited early. During school holidays from St Laurence College in Loughlinstown, County Dublin, she completed work experience at *Southside*, a Dublin-based publication, and immediately fell in love with the energy and urgency of deadline-driven writing.

She went on to study English at University College Dublin before completing a journalism qualification at Dublin City University. In 1987, she made the move to London — a city that would become her professional home for the rest of her life.

## Building a Career in Social Affairs and Health Media

Rachel began her London career as a reporter at the *London Irish News*, where she immersed herself deeply in the Irish expatriate community. She covered major political stories of the era, including the high-profile campaigns for the release of the Birmingham Six and the Guildford Four.

In 1990, she transitioned into social affairs journalism, joining *Social Work Today* as a reporter. She later moved to *Community Care* magazine, where she rose through the ranks from reporter to news editor (1994–1999) and ultimately to executive editor (1999–2002).

She was then appointed editor of the prestigious *Nursing Times*, a position she held from 2002 to 2008. In this role, Rachel demonstrated an instinctive understanding of what the nursing profession truly needed from its trade press — not empty praise or flattery, but honest, independent, and intelligent reporting that reflected the real, often challenging realities of life on the wards.

## From Journalism to Health Policy Communications

In 2009, Rachel stepped away from journalism and joined the Department of Health, where she worked at the heart of health policy communications until September 2025, when she became seriously ill. Throughout her adult life, she had lived with type 1 diabetes — a condition she managed with characteristic quiet determination.

## Honoring Her Father's Legacy

Rachel shared a particularly close bond with her father, James Downey, who passed away in 2016. In a deeply personal tribute to his memory, she ensured the posthumous publication of his book, *The Legacy of Gombeen Ireland* (2020) — a thoughtful and critical reflection on the failures of successive Irish governments in the decades following independence.

## Survived by Family

Rachel is survived by her husband, their two sons James and Colm, and her sister Vanessa. She is remembered not only as a skilled and principled journalist and communications professional, but as a passionate advocate for patients, fairness, and truth — values that defined both her career and her character.

Rachel Downey, health journalist and Head of PR at the Office of the Patient Safety Commissioner, has died aged 60. A tribute to her remarkable career.

Rachel Downey Obituary: Health Journalist and Patient Safety

large_1200.jpg

medium_1200.jpg

small_1200.jpg

thumbnail_1200.jpg

1200.jpg

Remembering Rachel Downey: A Life Dedicated to Health Journalism and Patient Safety

## The Unlikely Rise of a Health Innovation Powerhouse

Huddersfield is not a name typically associated with cutting-edge medical research. The West Yorkshire town has long been defined by its industrial and manufacturing roots. Yet today, it stands as a compelling example of how strategic partnerships between universities, NHS trusts, and private businesses can transform regional economies and accelerate healthcare innovation.

At the heart of this transformation is the University of Huddersfield's National Health Innovation Campus — an ambitious, eco-conscious development designed to become one of the most forward-thinking health research environments in the country.

## A Campus Built for the Future

Prof Liz Towns-Andrews, the driving force behind the campus, anticipates receiving approval next month for the third of seven planned eco-buildings earmarked for research and technology development near Huddersfield's town centre. This follows the opening in March of the £55 million Emily Siddon Centre — named after a local healthcare advocate — by the then health innovation minister, Zubir Ahmed.

The five-storey facility made headlines for housing the UK's first MRI scanner simulator: a machine that replicates the full experience of an MRI scan without the powerful magnets. "You genuinely wouldn't know it wasn't a fully operational machine," says the Yorkshire-born Towns-Andrews.

The campus also features Britain's first community diagnostic centre located on a university campus, developed alongside Calderdale and Huddersfield NHS Foundation Trust. All buildings have been constructed to meet rigorous environmental and wellbeing standards — known as the Well standard — placing them among the top 50 such facilities globally.

## Addressing Productivity Through Health

One of Towns-Andrews's central ambitions is tackling the region's persistently low worker productivity. Yorkshire and Humberside consistently records some of England's lowest economic outputs per hour worked, making the case for health-led investment all the more urgent.

"It wasn't exactly a complex equation — helping people stay healthy and capable of working would have the single greatest impact on productivity," she explains.

The campus is funded through a blend of public and private finance, with regional institutions also capitalising on a share of the £2 billion West Yorkshire investment zone. Since opening in September 2023, the hub has already supported around 380 companies, with that figure continuing to climb.

## A Model for Universities Under Financial Strain

The Huddersfield initiative arrives at a critical moment for British higher education. A recent report by the University of East London, which reviewed the financial accounts of 160 universities, found that nearly 40 institutions were approaching insolvency, with just two months of operating cash available. By contrast, Huddersfield recorded an operating surplus of approximately £10 million in the 2024–25 financial year.

With Oxford and Cambridge long established as magnets for biotech and medical spin-outs, universities in other regions are increasingly stepping up — building coalitions with health trusts and local councils to both drive research and support their surrounding economies.

"Combining the strengths of a council, a university, and a health trust gives you an extraordinarily powerful engine for economic growth," says Carson McCombe, head of innovation at the University of Huddersfield.

## Manchester Joins the Innovation Wave

Huddersfield is far from alone. Manchester is set to benefit from the opening of a major research and development centre belonging to Convatec — a FTSE 100 healthcare company — which has positioned the city alongside Boston, Massachusetts, as one of its twin global R&D hubs. The company told shareholders that staff should be embedded in Manchester specifically to tap into the collaborative networks offered by the city's universities and NHS trusts.

The move reflects a broader trend. Prof Tony Young, NHS England's national clinical director for innovation, notes that geopolitical uncertainty — including the unpredictable business climate created by Donald Trump's administration — has encouraged US health companies to redirect investment toward the UK. He also credits Chancellor Rachel Reeves with prioritising biotech and health as cornerstones of the government's industrial strategy.

Young, who launched five companies while training as a urology surgeon two decades ago, recalls having to fight the healthcare system every step of the way. The landscape has changed considerably since then. "Today, the NHS functions as an integrator — bringing together Nobel laureates, clinicians, investors, and innovators within a collaborative ecosystem designed to bring bold ideas to life," he says.

## Local Success Stories: Paxman Scalp Cooling

Just across the street from Huddersfield's Emily Siddon Centre sits a 125-year-old textile mill soon to be repurposed by Paxman Scalp Cooling — one of the town's fastest-growing businesses. The company produces a specialised head cap that prevents hair loss during chemotherapy treatment, a product now used by 97% of NHS trusts across the UK and distributed to hospitals in more than 50 countries. Over half of its exports go to the United States.

Richard Paxman, chief executive of the Stockholm-listed company and son of its founder, credits university and organisational partnerships with fuelling the company's innovation, expansion, and job creation over the years.

## Challenges and Setbacks

Despite these encouraging developments, the Labour government has encountered significant stumbles in its efforts to engage the health industry. AstraZeneca, the UK's largest pharmaceutical company, scrapped a £450 million investment in its vaccine manufacturing plant in Speke, Merseyside, following a reduction in government financial support — a high-profile blow to the administration's ambitions.

Meanwhile, American technology firms Palantir and Epic Systems have secured substantial NHS contracts, with Epic opening a sprawling 36-hectare campus near Bristol to deliver its patient booking and records platform. Critics have raised questions about the transparency and circumstances surrounding these deals.

## The Bigger Economic Picture

Despite these challenges, the strategic alliance between universities and health institutions is gaining recognition as a genuine driver of national prosperity. Universities UK, the sector's lobbying body, estimates that teaching, research, and innovation activities across UK higher education contribute £158 billion to the economy.

Research from the Federal Reserve Bank of Philadelphia reinforces this view on a global scale. A study examining the combined role of universities and hospitals in regional economies found that together, these institutions support 18 million jobs and generate more than £1 trillion in income in the United States alone — underscoring just how pivotal these anchor institutions have become to the modern economic landscape.

As Malcolm Press, president of Universities UK, puts it, the data is clear: universities and health trusts are no longer just places of learning and healing — they are engines of innovation, employment, and long-term economic resilience.

Discover how northern universities like Huddersfield and Manchester are partnering with NHS trusts to spark medical innovation and boost regional economic growt

Northern Universities and NHS Trusts Drive Health Innovation

large_5600.jpg

medium_5600.jpg

small_5600.jpg

thumbnail_5600.jpg

5600.jpg

How Northern Universities Are Partnering With NHS Trusts to Fuel Health Innovation

## Prostate Cancer: What Every Man Needs to Know

Prostate cancer is the most prevalent cancer among men in the United Kingdom, with approximately 55,000 new cases diagnosed annually. Statistically, one in every eight men will receive a prostate cancer diagnosis at some point in their lifetime — a figure that doubles to one in four for Black men.

## Understanding the Prostate Gland

The prostate is a small, walnut-sized gland located just beneath the bladder, nestled within the pelvis. It encircles the urethra — the tube responsible for carrying urine from the bladder through the penis and out of the body. Its position means that any abnormal growth in this gland can directly affect urinary function.

## How Prostate Cancer Develops

Prostate cancer occurs when cells in the prostate begin to multiply in an abnormal and uncontrolled manner. In many cases, the disease progresses slowly, and some men may live for years without experiencing any noticeable symptoms. In certain individuals, the cancer never causes significant health problems at all.

However, the disease can also take a more aggressive form, becoming life-threatening if left undetected or untreated. According to Cancer Research UK, prostate cancer claims around 12,200 lives every year in the UK. Early detection remains the most effective way to improve treatment outcomes.

## Who Is Most at Risk?

While prostate cancer can affect any man, certain groups face a significantly elevated risk:

- **Age** – The disease is most common in men over 75. Cases in men under 50 are relatively rare.
- **Ethnicity** – Black men face twice the average risk, with a one in four lifetime chance of diagnosis.
- **Family history** – Having a close male relative — such as a father, brother, grandfather, or uncle — who has had prostate cancer raises your personal risk considerably.
- **Genetics** – Men who carry a BRCA2 gene variant and have a family history of breast, ovarian, pancreatic, or prostate cancer are at particularly high risk.

For a quick initial assessment, Prostate Cancer UK offers a free 30-second online risk checker. Men who believe they may be at elevated risk are strongly encouraged to speak with their GP.

## Recognising the Warning Signs

One of the challenges with prostate cancer is that it often produces no symptoms in its early stages. When symptoms do appear, they may include changes in urinary habits, discomfort during urination, or other pelvic issues. It is important to note that these symptoms can also result from other, less serious conditions — but any persistent changes should be assessed by a doctor without delay.

## How Is Prostate Cancer Diagnosed?

There is currently no single definitive test for prostate cancer. Diagnosis typically involves a combination of the following:

### PSA Blood Test
The prostate-specific antigen (PSA) blood test measures the level of a particular protein in the blood. Elevated PSA levels can indicate prostate cancer, but they can also be caused by infection or other non-cancerous conditions. This means a raised PSA result does not automatically confirm cancer.

Men over the age of 50 can generally request a PSA test through their GP. Before undergoing the test, patients are advised to avoid sexual activity and vigorous exercise — such as cycling — for at least 48 hours, as these activities can influence results.

### Scans and Biopsy
Doctors may also recommend an MRI scan to gain a clearer picture of the prostate. If abnormalities are detected, a biopsy — the removal of a small tissue sample for laboratory analysis — may be carried out to confirm whether cancer is present. Researchers are also actively exploring whether combining MRI scans with PSA testing could lead to more accurate diagnoses.

## Screening: Who Qualifies?

Prostate cancer remains the only major cancer in the UK without a national screening programme. This is largely because the existing blood test carries risks — it can miss aggressive cancers while also detecting slow-growing tumours that may never require treatment, potentially leading to unnecessary interventions.

In May 2026, UK ministers endorsed a recommendation from the National Screening Committee that routine screening should be limited to a small, clearly defined high-risk group. Specifically, men who carry the BRCA2 gene variant and have a relevant family history of cancer will be invited for a PSA blood test every two years between the ages of 45 and 61. This is expected to apply to several thousand men annually, many of whom are already being monitored through NHS genetics clinics.

A separate ongoing trial is also inviting tens of thousands of Black men aged 45 to 74 for prostate checks, as researchers seek better and more equitable methods of detecting the disease.

High-profile advocates, including professional cyclist Sir Chris Hoy — who has publicly disclosed that his own prostate cancer diagnosis is terminal — have championed broader access to regular testing for at-risk men.

## What Should You Do?

If you are concerned about your prostate health, do not wait for symptoms to appear. Speak to your GP, use Prostate Cancer UK's online risk checker, and stay informed. Early detection saves lives.

Learn the key symptoms of prostate cancer, who is most at risk, and how the disease is diagnosed. Essential health information for every man in the UK.

Prostate Cancer Symptoms, Risks & Diagnosis Explained

68492b60-5aa7-11f1-b277-cd187c78657d.jpg

Prostate Cancer: Key Symptoms, Risk Factors, and What Every Man Should Know

## NHS Rolls Out Cutting-Edge Radiotherapy for Prostate Cancer Patients

Thousands of men across England diagnosed with prostate cancer are set to benefit from a highly advanced form of radiotherapy available on the NHS — one that reduces the number of required treatment sessions from 20 down to just five.

The technique, known as SABR (stereotactic ablative radiotherapy), delivers an exceptionally precise and high-powered beam of radiation directly at cancerous tissue, minimising damage to surrounding healthy cells. Senior oncologists say it represents a significant improvement over conventional radiotherapy, both in terms of effectiveness and reduced side effects.

## What Is SABR and Who Will It Help?

SABR is not an entirely new treatment — it has already been used successfully on patients with lung and brain cancers. However, this marks the first time it will be made available to men with low- and intermediate-risk prostate cancer outside of clinical trials.

Approximately 55,000 men receive a prostate cancer diagnosis in England every year. Of those, roughly 17,500 fall into the low- or intermediate-risk category. NHS modelling estimates that around 3,500 of those men — approximately one in five — are likely to choose this new form of treatment.

The relatively modest uptake is partly explained by the fact that many men diagnosed with low-risk prostate cancer opt for active monitoring rather than immediate intervention, given the typically slow-growing nature of the disease.

## Nationwide Rollout Expected Within Weeks

NHS England has confirmed that all 48 radiotherapy centres operating across the country are expected to begin offering SABR to eligible prostate cancer patients within weeks.

Professor Peter Johnson, National Clinical Director for Cancer, acknowledged that while the advancement will not apply to every prostate cancer patient, it represents a meaningful step forward in cancer care.

"This technology lets us focus a powerful and precise beam of radiotherapy directly on to the cancer, limiting the damage to healthy cells," he said. "And the fact it can be delivered in 15 fewer doses will help men get back to living their lives far more quickly."

Amy Rylance of Prostate Cancer UK welcomed the news, describing it as a significant breakthrough. "It will massively reduce the burden that cancer places on patients and their loved ones," she said. The charity also expressed hope that SABR will eventually become accessible to men with high-risk prostate cancer as well.

## Trials Already Underway for High-Risk Patients

Clinical trials are currently in progress to determine whether SABR can be safely and effectively extended to high-risk prostate cancer cases — a development that could widen its impact considerably.

## One Patient's Experience: 'An Absolute Godsend'

Edwin Lambert, a 70-year-old from Suffolk, is among the patients currently participating in one of these high-risk trials. Diagnosed with prostate cancer in January 2025, he initially underwent hormone therapy, which brought with it a range of difficult side effects including fatigue, mood swings, hot flushes, and loss of libido.

He subsequently received the precision radiotherapy targeting both his prostate and nearby lymph nodes. Comparing his experience to that of other patients he observed undergoing traditional radiotherapy during his hospital visits, Lambert noted a striking difference.

"They looked dreadful," he said of those receiving conventional treatment, citing the toll of repeated sessions. His own side effects were limited primarily to increased urinary frequency during and shortly after the treatment.

Within just five weeks of completing his course of radiotherapy, Lambert was back on his feet — quite literally — participating in an archaeological dig he had been planning for some time.

"This treatment was an absolute godsend," he said.

## A Step Forward in Cancer Care

The rollout of SABR for prostate cancer represents a broader shift toward more targeted, patient-centred cancer treatment. By combining clinical precision with a dramatically reduced treatment schedule, the NHS is offering men not only better outcomes, but a faster return to the lives they cherish.

The NHS is rolling out SABR precision radiotherapy for prostate cancer, cutting treatment sessions from 20 to just 5 and reducing side effects for thousands of 

NHS Cuts Prostate Cancer Radiotherapy Sessions from 20 to 5

461b52a0-6490-11f1-8546-8f19e4fe30f4.jpg

NHS to Offer Precision Radiotherapy for Prostate Cancer, Cutting Treatment Sessions from 20 to Just Five

## America Is Running Out of Time to Prepare for Deadly Heat

As another brutal summer approaches, a sobering new study is raising urgent alarms about the long-term consequences of extreme heat across the United States. According to research published in the American Geophysical Union journal *GeoHealth*, the next 15 years could witness a dramatic surge in heat-related hospitalizations — with the numbers potentially doubling by the year 2040.

## Hospitalizations Set to Skyrocket

Researchers project that annual heat-related emergency department visits and hospitalizations will climb from approximately 109,000 cases per year to as many as 237,000 by 2040. That sharp increase would, in turn, drive annual healthcare costs for heat-related conditions to more than $1 billion — nearly double current spending levels.

The findings underscore a growing public health emergency. Extreme heat already claims more American lives each year than every other type of severe weather combined, and heat-related deaths have surged by over 50% during the past two decades alone.

## Who Is Most at Risk?

The burden of extreme heat does not fall equally. The study, which analyzed 53 of the country's largest metropolitan areas, found that:

- **California and the Las Vegas region** are expected to record the highest total number of heat-related health incidents.
- **The northeast and Ohio Valley**, regions historically unaccustomed to extreme heat, are projected to suffer the most severe health consequences during major heat events.
- **Elderly individuals and those with pre-existing health conditions** face the greatest danger.
- **Lower-income households** are disproportionately vulnerable, particularly those unable to afford air conditioning, those working outdoors, or those living in homes not designed to withstand high temperatures.

"Heat is an amplifying event," said Vivek Shandas, a professor at Portland State University and co-author of the study. "If you are already struggling with a pre-existing condition, there's a good chance it will lead to some kind of illness like heatstroke or even death."

## A Perfect Storm of Risk Factors

The crisis is being compounded by several converging pressures. The US recorded its hottest March ever this year, and forecasters are warning of above-average summer temperatures alongside a heightened risk of widespread wildfires — consistent with broader climate trends driven by fossil fuel emissions.

At the same time, energy costs are climbing sharply. The average American household is expected to spend close to $800 on electricity this summer, a rise of more than 10% compared to last year, according to a report from the National Energy Assistance Directors Association (NEADA) and the Center for Energy Poverty and Climate.

"When temperatures break records, utility bills often do too," said Mark Wolfe, executive director of NEADA. "For families already struggling to make ends meet, higher cooling costs can force difficult choices between paying utility bills and covering other necessities such as food, rent, or medicine."

Meanwhile, federal support for heat mitigation has been diminishing. The current administration has cut programs designed to help cities manage extreme heat, leaving many municipalities — especially in northern latitudes — without adequate resources or infrastructure.

## Cities Are Dangerously Unprepared

Shandas and his co-author Stephan Brown of CAPA Strategies paint a stark picture of a nation ill-equipped for the climate challenges ahead.

"There is a staggering cost to society we are going to see over the next 15 years," Shandas warned. "It's not that we will see a plateau of heat-related illnesses and simply acclimate — there is going to be a sustained increase."

Many cities, particularly those in northern regions, are described as "woefully unprepared" for the escalating threat. Public health agencies are already under pressure, and the rollback of climate-focused interventions is leaving communities exposed.

"It's a moment where a number of trains are heading toward each other on the same track," Shandas said. "The heat risk isn't growing just because of the temperature — it's growing because more vulnerable people are living in places that are experiencing more extreme heat."

## The Urgent Need for Action

The message from researchers is clear: without meaningful investment in heat resilience, cooling infrastructure, and support for vulnerable populations, the human and financial toll of extreme heat will only grow. With this summer already shaping up to be another record-breaker, the window for preparation is narrowing fast.

A new study finds heat-related US hospitalizations may double by 2040, pushing healthcare costs past $1B as cities struggle to cope with rising temperatures.

US Heat Hospitalizations Could Double by 2040, Study Warns

large_5602.jpg

medium_5602.jpg

small_5602.jpg

thumbnail_5602.jpg

5602.jpg

Heat Crisis Ahead: US Hospital Visits Could Double by 2040 as Extreme Temperatures Surge

## GLP-1 Medications Show Unexpected Promise in Cancer Prevention

The class of drugs that transformed the treatment of obesity and type 2 diabetes may be quietly rewriting the rules of cancer prevention. A growing body of research suggests that GLP-1 receptor agonists — medications like semaglutide and tirzepatide — could not only reduce the risk of developing certain cancers but may also slow the progression of existing ones.

While these findings are still emerging, they have captured the attention of oncologists, endocrinologists, and researchers worldwide who are eager to understand what is driving this potentially groundbreaking connection.

## What the Research Is Showing

Several recent studies have pointed to a meaningful association between GLP-1 drug use and reduced cancer incidence. Patients taking these medications appear to face lower risks across multiple cancer types, a pattern that has prompted serious scientific inquiry into the underlying causes.

At first glance, the explanation seemed straightforward. Weight loss itself is a well-documented factor in lowering cancer risk, since excess body fat is linked to chronic inflammation and hormonal imbalances that can fuel tumor growth. Given that GLP-1 drugs are highly effective at promoting significant weight reduction, it seemed reasonable to credit the pounds lost for the cancer protection observed.

However, researchers now believe the story is considerably more complex — and more interesting.

## Beyond Weight Loss: Other Pathways Under Investigation

### Brain and Metabolic Mechanisms

Scientists are increasingly focused on the possibility that GLP-1 drugs act through pathways that have nothing to do with weight loss. GLP-1 receptors are found not only in the pancreas and gut but also throughout the brain and in various other tissues across the body.

This widespread receptor distribution suggests that these medications may influence metabolic and neurological processes in ways that independently create an environment less hospitable to cancer development and growth.

### Inflammation and Cellular Health

One leading theory centers on the anti-inflammatory properties associated with GLP-1 receptor activation. Chronic inflammation is one of the most significant drivers of cancer development, and if these drugs can reduce systemic inflammation beyond what weight loss alone achieves, that could account for a substantial portion of the protective effect observed in patients.

Researchers are also exploring whether GLP-1 medications may influence cell proliferation, apoptosis (programmed cell death), and other fundamental biological processes that determine whether abnormal cells survive and multiply.

## Why This Research Matters

Cancer remains one of the leading causes of death globally, and any intervention capable of meaningfully reducing its incidence or slowing its progression would represent a major public health advancement. The widespread adoption of GLP-1 medications in recent years provides researchers with an unprecedented opportunity to study large populations of users over time.

If ongoing investigations confirm that these drugs carry genuine cancer-fighting properties independent of weight loss, it could open entirely new conversations about how and when they should be prescribed — potentially extending their application well beyond diabetes and obesity management.

## What Comes Next

The scientific community acknowledges that much work remains to be done. Researchers are calling for rigorous clinical trials specifically designed to isolate the cancer-related effects of GLP-1 drugs, separate from the confounding influence of weight reduction.

Until those studies deliver clearer answers, the emerging data is best viewed as compelling and hypothesis-generating rather than conclusive. Nevertheless, the trajectory of the research is exciting — and the possibility that a single class of drugs could simultaneously address obesity, diabetes, and cancer risk is a prospect that the medical world is watching very closely.

New research suggests GLP-1 weight loss drugs may prevent cancer and slow its growth. Scientists explore brain and metabolic pathways beyond weight loss.

GLP-1 Drugs and Cancer Protection: What Research Shows

large_jpeg

medium_jpeg

small_jpeg

thumbnail_jpeg

jpeg

GLP-1 Drugs May Shield Against Cancer — Here's What Scientists Are Discovering

## Why Your Five-a-Day Might Not Be Enough for Your Heart

For decades, the advice has been simple: eat five portions of fruit and vegetables every day. But groundbreaking new research suggests that what you choose to put on your plate matters far more than how much of it you eat — especially when it comes to protecting your heart.

A large-scale study involving 30,000 participants from both the United States and the United Kingdom has found that even among people who consistently meet the five-a-day target, many are still falling short of a critical group of nutrients known as **flavanols**.

## What Are Flavanols and Why Do They Matter?

Flavanols are a type of antioxidant found naturally in certain plant-based foods. According to the research, published in the journal *Food and Function*, these compounds play a meaningful role in supporting cardiovascular health by reducing inflammation, improving circulation, and helping to maintain blood vessel flexibility.

Despite their importance, fewer than one in five people consume the recommended 500mg of flavanols per day — a threshold identified by the US Academy of Nutrition and Dietetics as beneficial for heart health. Notably, the NHS does not currently set an official daily flavanol target.

## The Best Food Sources of Flavanols

Researchers identified several foods that deliver notably high levels of flavanols per portion. To meaningfully increase your daily intake, consider regularly including the following in your diet:

- **Blueberries**
- **Blackberries**
- **Plums**
- **Cherries**
- **Broad beans**
- **Green tea**

Lead investigator Dr. Javier Ottaviani explained that a few targeted food swaps could "make a real difference" to how much of these beneficial compounds the body actually absorbs. "Most people assume that eating plenty of fruit and vegetables covers this," he said, "but what this research shows is that the specific choices you make matter far more than the total amount."

## Not All Five-a-Days Are Created Equal

Professor Gunter Kuhnle of the University of Reading, one of the study's investigators, acknowledged that the five-a-day message remains sound — but argued it may need greater refinement. "Different fruits and vegetables offer very different nutritional benefits beyond vitamins and minerals," he noted. "As our understanding of these compounds grows, there is a real opportunity to make dietary guidance more specific and more effective."

The study used both dietary tracking data and urine biomarkers to accurately measure participants' flavanol absorption — a more reliable method than self-reported dietary surveys alone.

## What About Dark Chocolate?

The research team has previously collaborated with chocolate manufacturer Mars Inc., which has been exploring cocoa-based flavanol supplements. Cocoa is a recognised source of flavanols, and dark chocolate is often considered the healthier option over milk chocolate due to its lower sugar content and higher cocoa concentration.

However, the British Heart Foundation (BHF) cautions that flavanol levels in commercial chocolate products vary considerably. Two to three squares of dark chocolate may contain anywhere between 22 and 73mg of flavanols, while the same amount of milk chocolate typically provides just 3 to 7mg.

## Experts Urge Caution on Cardiovascular Claims

While the findings are promising, some specialists are calling for restraint before drawing firm conclusions. Professor Naveed Sattar of the University of Glasgow pointed out that although certain small-scale trials have shown modest improvements in blood pressure, there is currently insufficient evidence to confirm that increasing flavanol intake directly reduces the risk of serious cardiovascular events such as heart attacks or strokes. He stressed that further clinical trials are needed.

Professor Ana Rodriguez-Mateos, a nutrition expert at King's College London, added that flavanol content in fruit and vegetables can fluctuate significantly depending on a wide range of factors — much like fibre content — and that this variability warrants deeper investigation.

## Individual Differences Play a Role Too

Dell Stanford of the BHF highlighted another layer of complexity: how the body processes flavanols is not the same for everyone. The quantity of flavanols in any given food depends on where it was grown, the local climate, its ripeness at the time of consumption, and how it has been stored or prepared.

Furthermore, gut bacteria play a significant role in breaking down flavanols into forms the body can use — and since everyone's gut microbiome is unique, the actual health benefits individuals derive from these nutrients may differ considerably.

## The Bottom Line

Both the BHF and the British Nutrition Foundation maintain that the most effective way to support heart health remains following established dietary guidelines: eating a balanced, varied diet rich in a wide range of fruits and vegetables. However, this new research adds an important nuance — being more intentional about *which* fruits and vegetables you choose could give your cardiovascular health a meaningful extra boost.

New research reveals that specific fruits and vegetables rich in flavanols — not just any five-a-day — are key to protecting your heart health.

Best Flavanol-Rich Foods for a Healthier Heart

966dc9e0-60e9-11f1-92fe-5faf9b4f0321.jpg

The Specific Fruits and Vegetables Your Heart Actually Needs Every Day

## Weight-Loss Drugs Are Quietly Reshaping the Protein Market

The explosive rise of GLP-1 weight-loss medications like Mounjaro is sending shockwaves far beyond the pharmacy — all the way into the global dairy supply chain. Whey protein, a byproduct of cheese production long favored by athletes and fitness enthusiasts, is now at the center of a mounting supply crisis as demand dramatically outpaces availability.

Industry analysts are sounding the alarm over a potential shortage, with prices climbing to levels never previously recorded — and no immediate relief in sight.

## Prices Have Skyrocketed Fivefold

The numbers tell a striking story. Food-grade whey powder across north-west Europe is now trading at roughly €1,700 per tonne — an all-time high. Prices have surged more than 50% since the beginning of the year alone, according to data from DCA Market Intelligence.

The picture becomes even more dramatic when viewed over a longer timeframe. Commodity intelligence platform Vesper reports that whey protein concentrate at 80% purity jumped from £4,302 per tonne in June 2023 to an extraordinary £23,751 per tonne by June of this year — a fivefold increase in just two years.

## Why GLP-1 Drugs Are Driving Demand

Whey protein is derived from milk during the cheese-making process and is considered a complete protein, meaning it contains all nine essential amino acids. Its high bioavailability makes it one of the most effective supplements available for supporting muscle growth and recovery.

For people using GLP-1 medications, maintaining adequate protein intake isn't just recommended — it's essential. These drugs work by suppressing appetite and reducing overall food consumption, which can inadvertently lead to muscle loss alongside fat loss. Health professionals routinely advise GLP-1 users to deliberately increase protein intake to counteract this effect, creating a significant new wave of demand.

Beyond GLP-1 users, broader cultural shifts toward high-protein diets have amplified the pressure. Protein-enriched products — from popcorn and chips to doughnuts — have flooded mainstream supermarket shelves, pulling whey into an entirely new category of food manufacturing.

## Supply Is Struggling to Keep Up

Jasper Endlich, an analyst at Vesper, described the situation plainly: "If you look at overall supply and demand, the market is still finding a home for the product, but there's clearly a shortage in the sense that people want more than there physically is available. Manufacturers would like to produce more and build safety stocks, but they haven't been able to do that."

Endlich noted that the market is beginning to adapt. New production facilities are opening, and some manufacturers are blending whey with milk protein to reduce costs while maintaining overall protein content — a strategy that can cut ingredient expenses by half or even two-thirds.

A report from the United States Department of Agriculture's dairy market news division confirms the tightening supply, particularly for whey protein concentrate at 34% purity — a widely used commercial dairy ingredient. Prices for this product are rising across the board, with the sharpest increases at the premium end. Several suppliers are reportedly already sold out for the remainder of 2026, and at least one manufacturer is expected to exit WPC 34% production entirely after the summer, a development that industry participants believe will further strain availability.

## Small Businesses Are Feeling the Squeeze

While large corporations may have the resources to absorb rising costs and secure preferential supply allocations, smaller operators are finding the situation increasingly difficult to navigate.

Erika Tamayo, founder of premium protein brand Hermosa, which sources ingredients from UK farmers, has watched costs spiral quarter after quarter. "On the last two years, we've noticed every quarter the price is soaring up," she said. "We are managing to source protein, but we're buying it at double the cost compared to last quarter."

Tamayo explained that she has held off passing the full cost increase on to customers for now, but acknowledged that a price adjustment will eventually become unavoidable. "We are now all fighting for stock allocation," she added. "Bigger players have more possibilities, so they don't have to compromise. For a small business with a small range of products, it is harder."

She also highlighted the broader market shift triggered by GLP-1 adoption: "Once GLP-1s started soaring, people realised how important protein is in their diet. Then loads of products in mainstream supermarkets started adding whey protein to everything. Everything now has protein in it because of the focus on diets."

For brands like hers, planning ahead has become a logistical challenge in itself — requiring months of advance purchasing while navigating unpredictable supply windows each quarter.

## What Comes Next

The whey protein market faces a complex road ahead. Demand shows no sign of slowing, driven by the continued uptake of GLP-1 medications and the mainstream embrace of high-protein eating. Supply, while beginning to respond through new capacity and ingredient substitutions, has not yet caught up.

For consumers, this may eventually translate into higher prices on protein supplements and protein-enriched foods. For the industry, it represents both a significant challenge and a signal that the intersection of pharmaceutical innovation and nutrition science is reshaping global food supply in ways few anticipated.

GLP-1 weight-loss drugs are fueling record whey protein demand. Prices have risen fivefold and suppliers are selling out. Here's what's driving the crisis.

Whey Protein Shortage Looms as GLP-1 Drugs Spike Demand

large_4148.jpg

medium_4148.jpg

small_4148.jpg

thumbnail_4148.jpg

4148.jpg

Weight-Loss Drug Boom Drives Whey Protein Prices to Record Highs — and a Shortage May Be Coming

## The Hidden Cost of Rapid Weight Loss on Obesity Medications

Obesity injections like Wegovy and Mounjaro have transformed the weight loss landscape — but they come with an unwanted side effect that's drawing growing attention. According to new research published in *Nature Medicine*, approximately one-third of the weight shed while using GLP-1 medications can come from muscle tissue rather than fat. Now, a new drug called **apitegromab** may offer a solution.

## What Is 'Ozempic Butt' — and Why Does It Happen?

As people rapidly lose weight on GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro, some experience a significant reduction not just in fat, but also in muscle and tissue volume. One widely discussed consequence is a flattened or sagging appearance to the buttocks — colloquially known as **'Ozempic butt.'**

Plastic surgeons across the United States report a sharp increase in patient consultations related to this issue, and while it carries no formal medical diagnosis, its impact on body confidence is real.

Experts believe this muscle depletion stems from the speed of weight loss itself, rather than any direct effect of the medication. GLP-1 drugs work by suppressing appetite and prolonging feelings of fullness, causing users to consume significantly fewer calories — and when the body loses weight quickly, muscle is often sacrificed alongside fat. Unlike fat, muscle is notoriously difficult to rebuild once lost.

## How Apitegromab Could Help Preserve Muscle

A clinical trial involving 102 adults — the majority of whom were women — has revealed encouraging results for apitegromab as a companion treatment to obesity medication. Participants who received apitegromab alongside Mounjaro retained approximately **1.9kg (55%) more lean muscle mass** compared to those given a placebo.

In the apitegromab group, muscle accounted for just **14.6% of total weight lost**, versus **30.2%** in the placebo group — a notable difference that suggests the drug may help users lose fat while protecting their muscles.

Apitegromab functions by targeting and blocking a protein responsible for triggering muscle breakdown. It is also currently being researched as a potential therapy for other muscle-affecting conditions, including spinal muscular atrophy.

### Important Caveats

Despite the promising data, experts urge caution. The trial ran for only six months, and independent researchers emphasize that these findings should be regarded as **early encouraging evidence** rather than confirmed clinical proof.

Dr. Marie Spreckley of Cambridge University, who was not involved in the study, called for larger, longer-term trials to determine whether preserving muscle mass genuinely improves strength, wellbeing, and overall health outcomes over time.

Dr. Brendan Gabriel, a nutrition and health specialist at the University of Aberdeen, added that apitegromab may not be appropriate for all GLP-1 users — but could prove particularly beneficial for individuals experiencing unusually rapid muscle loss.

At present, apitegromab is only accessible through clinical trials and must be administered intravenously. The drug's manufacturer — which also funded the study — is currently exploring whether a self-injectable pen format could be developed, similar to how GLP-1 medications are delivered.

## How to Protect Your Muscles While on Weight Loss Medication

While apitegromab awaits further evaluation, people using GLP-1 drugs are already encouraged to take practical steps to preserve their muscle mass.

### Strength Training

You don't need a gym membership to maintain muscle. Any activity that challenges your muscles beyond their normal workload counts as strength training — and the benefits compound over time. The NHS recommends aiming for **at least two sessions per week**, which can include:

- Bodyweight exercises such as squats, lunges, and push-ups
- Resistance band workouts
- Weight lifting or dumbbell exercises
- Yoga or Pilates
- Heavy gardening or carrying loads

Begin at a manageable level and gradually increase intensity as your strength improves.

### Prioritise Protein Intake

Diet plays an equally important role. Research indicates that consuming **20–40 grams of protein per meal** supports the maintenance and development of muscle mass. A practical guideline is to fill roughly a quarter of your plate with protein-rich foods at every meal.

Excellent protein sources include:

- Meat and poultry
- Fish and seafood
- Beans, lentils, and chickpeas
- Eggs
- Greek yoghurt and dairy products
- Nuts and seeds

## The Bottom Line

GLP-1 medications remain powerful and legitimate tools for managing obesity — but they are not intended as cosmetic quick fixes, and health professionals strongly advise against misusing them for short-term aesthetic goals. As the science around these drugs continues to evolve, treatments like apitegromab represent a genuinely exciting frontier in making weight loss both effective and healthier for the whole body.

A new drug called apitegromab may help people on GLP-1 obesity jabs like Ozempic preserve muscle mass and avoid unwanted body composition changes.